Mary Hitchcock Memorial Hosp
- Type
- Teaching hospital
- Where
- Lebanon, NH
- Medicare CCN
- 300003
- Received
- $3,166,836 in 548 records, 2021 ($966,819 general, $2,200,017 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 40 | $966,819 |
| 2021 | Research payment | 508 | $2,200,017 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 508 | $2,200,017 |
| Consulting Fee | 12 | $827,510 |
| Grant | 5 | $76,400 |
| Education | 5 | $31,338 |
| Long term medical supply or device loan | 7 | $13,254 |
| Debt forgiveness | 4 | $7,330 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $5,500 |
| Space rental or facility fees (teaching hospital only) | 5 | $4,400 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $1,085 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $126,963 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $75,166 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $53,569 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology | 2021 | |
| 2021-12-31 | AstraZeneca UK Limited | $8,311 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non small Cell Lung Cancer | 2021 |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,919 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $1,807 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $686 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 St | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $486 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-sma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $150 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Sche | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2021 |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $641 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Kiniksa Pharmaceuticals, Ltd. | $294 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-12-20 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-20 | Boston Scientific Corporation | $350 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | CHAMPION AF | 2021 |
| 2021-12-20 | Genentech, Inc. | $130 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | 2021 |
| 2021-12-17 | Merck Sharp & Dohme LLC | $154,741 | Research payment | Cash or cash equivalent | Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-17 | W. L. Gore & Associates, Inc. | $2,071 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2021 |
| 2021-12-15 | Kaneka Medical America LLC | $1,718 | Consulting Fee (12 payments) | Cash or cash equivalent | LIPOSORBER Device, Lipid Apheresis | 2021 | |
| 2021-12-14 | GlaxoSmithKline, LLC. | $832 | Research payment | Cash or cash equivalent | A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI | 2021 | |
| 2021-12-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,876 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of ILUMYA to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Complet | 2021 |
| 2021-12-10 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-12-10 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-12-08 | Merck Sharp & Dohme LLC | $15,249 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2021 |
| 2021-12-08 | Medical Device Business Services, Inc. | $1,664 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-12-08 | Medical Device Business Services, Inc. | $100 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-12-01 | VERTEX PHARMACEUTICALS INCORPORATED | $5,954 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i | 2021 | |
| 2021-12-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-29 | Takeda Pharmaceuticals U.S.A., Inc. | $747 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-11-24 | Relievant Medsystems, Inc. | $552 | Research payment | Cash or cash equivalent | Intracept Device, Pain | Intracept | 2021 |
| 2021-11-19 | Medical Device Business Services, Inc. | $1,192 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2021 |
| 2021-11-19 | MicroVention, Inc. | $110 | Research payment | Cash or cash equivalent | HydroCoil Helical Device, Neurological Product | NULL | 2021 |
| 2021-11-16 | Celgene Corporation | $258 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | A Phase 3B Randomized Study of Lenalidomide (CC-50 | 2021 |
| 2021-11-15 | Genentech, Inc. | $3,800 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | TECENTRIQ PLUS AVASTIN FOLLOWING CURATIVE RESECTION IN PATIENTS AT HIGH RISK OF RECURRENCE | 2021 |
| 2021-11-15 | Medical Device Business Services, Inc. | $3,243 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2021 |
| 2021-11-12 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-12 | Edwards Lifesciences Corporation | $25,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-12 | Bayer Healthcare Pharmaceuticals Inc. | $309 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2021 |
| 2021-11-08 | Medical Device Business Services, Inc. | $6,503 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2021 |
| 2021-11-05 | W. L. Gore & Associates, Inc. | $2,829 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2021 |
| 2021-11-05 | W. L. Gore & Associates, Inc. | $2,450 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2021 |
| 2021-11-04 | GlaxoSmithKline, LLC. | $50 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2021 | |
| 2021-11-03 | FUJIFILM SonoSite, Inc. | $196 | Education | In-kind items and services | SonoSite Edge II Device, Medical Device | 2021 | |
| 2021-11-02 | Boston Scientific Corporation | $25,000 | Grant | Cash or cash equivalent | GENERAL EMBOLICS Device, PAIN MANAGEMENT | 2021 | |
| 2021-11-02 | Medline Industries LP | $700 | Research payment | In-kind items and services | Compass Thoracentesis Device, Medical supplies | Pleural manometry for the characterization of spontaneous and tension pneumothorax | 2021 |
| 2021-11-01 | Janssen Research & Development, LLC | $5,200 | Research payment | Cash or cash equivalent | A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study | 2021 | |
| 2021-11-01 | Edwards Lifesciences Corporation | $908 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2021 | |
| 2021-11-01 | Boston Scientific Corporation | $650 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASSESSMENT OF THE WATCHMAN FLX DEVICE IN PATIENTS UNSUITABLE | 2021 |
| 2021-11-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-10-29 | W. L. Gore & Associates, Inc. | $2,600 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | TAMBE Initial Feasibility Assessment of the GORE EXCLUDER Juxtarenal and Thoracoabcominal Branch System in the Treatmen | 2021 |
| 2021-10-28 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-10-26 | Abbott Laboratories | $3,048 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-10-26 | Genentech, Inc. | $2,334 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2021 |
| 2021-10-26 | Eli Lilly and Company | $70 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 | |
| 2021-10-26 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-10-25 | GlaxoSmithKline, LLC. | $84,120 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2021 | |
| 2021-10-23 | Amgen Inc. | $3,264 | Research payment | Cash or cash equivalent | Otezla Drug, Inflammation | PPSO-003/20200056 (SPROUT) | 2021 |
| 2021-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $21,858 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-10-21 | Bayer Healthcare Pharmaceuticals Inc. | $2,054 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2021 |
| 2021-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $325 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-10-20 | Davol Inc. | $30,000 | Research payment | Cash or cash equivalent | PHASIX Device, BD Interventional Surgery | 59245169 | 2021 |
| 2021-10-18 | Boston Scientific Corporation | $997 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | CHAMPION AF | 2021 |
| 2021-10-13 | Masimo Corporation | $74,929 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-13 | Allergan, Inc. | $4,126 | Research payment | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2021 |
| 2021-10-08 | Incyte Corporation | $132 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $43 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-10-07 | Takeda Pharmaceuticals U.S.A., Inc. | $31,682 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-10-06 | SANOFI PASTEUR INC. | $8,970 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2021 | |
| 2021-10-05 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-10-04 | Genentech, Inc. | $2,412 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | 2021 |
| 2021-10-04 | Boston Scientific Corporation | $1,150 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASSESSMENT OF THE WATCHMAN FLX DEVICE IN PATIENTS UNSUITABLE | 2021 |
| 2021-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $488 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2021 |
| 2021-10-04 | Gilead Sciences, Inc. | $351 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase III Study to Assess the Efficacy and Safe | 2021 | |
| 2021-10-03 | NEUROPACE, INC. | $450 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $150 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $30 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $28 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $28 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $28 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-03 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-10-01 | ABBVIE INC. | $1,000 | Grant | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2021 | |
| 2021-10-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-09-30 | Abbott Laboratories | $15,000 | Education | Cash or cash equivalent | 2021 | ||
| 2021-09-30 | E.R. Squibb & Sons, L.L.C. | $6,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Peri-Adjuvant NSCLC Nivo Mono | 2021 |
| 2021-09-30 | Intuitive Surgical, Inc. | $1,807 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-09-28 | AstraZeneca Pharmaceuticals LP | $22,432 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase 1 and 2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab MEDI4736 Plus the Toll Like Receptor Ag | 2021 |
| 2021-09-28 | Eisai Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | 2021 | |
| 2021-09-27 | Eli Lilly and Company | $204 | Research payment | In-kind items and services | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS -ANASTROZOLE OR LETROZOL | 2021 | |
| 2021-09-26 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-09-26 | NEUROPACE, INC. | $15 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-09-24 | W. L. Gore & Associates, Inc. | $650 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-09-23 | Medtronic, Inc. | $25,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-22 | Gilead Sciences, Inc. | $2,309 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 | |
| 2021-09-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,528 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of ILUMYA to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Complet | 2021 |
| 2021-09-20 | ZOLL Medical Corporation | $47,490 | Research payment | Cash or cash equivalent | Device, Resuscitation | CPR ventilation / NIRS | 2021 |
| 2021-09-20 | US ENDOSCOPY | $2,000 | Research payment | Cash or cash equivalent | TruFreeze Device, Gastroenterology | 2021 | |
| 2021-09-20 | Boston Scientific Corporation | $1,300 | Research payment | Cash or cash equivalent | DESBTK Device, Clinical Trial Product | SFA DES PIVOTAL | 2021 |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $765 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $638 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $358 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $358 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $263 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $250 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | Boston Scientific Corporation | $195 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | CHAMPION AF | 2021 |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $179 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-20 | GlaxoSmithKline, LLC. | $100 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2021 | |
| 2021-09-20 | Kiniksa Pharmaceuticals, Ltd. | $98 | Research payment | In-kind items and services | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and P | 2021 | |
| 2021-09-17 | W. L. Gore & Associates, Inc. | $5,336 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2021 |
| 2021-09-17 | W. L. Gore & Associates, Inc. | $5,278 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2021 |
| 2021-09-17 | W. L. Gore & Associates, Inc. | $2,184 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2021 |
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-16 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | 2021 | |
| 2021-09-15 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-09-15 | Medical Device Business Services, Inc. | $1,500 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-09-15 | Medical Device Business Services, Inc. | $1,248 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-09-14 | Masimo Corporation | $78,763 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-14 | Allergan, Inc. | $1,934 | Research payment | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2021 |
| 2021-09-13 | Genentech, Inc. | $5,887 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-09-13 | Incyte Corporation | $3,718 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants | 2021 | |
| 2021-09-13 | Incyte Corporation | $3,380 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants | 2021 | |
| 2021-09-10 | W. L. Gore & Associates, Inc. | $1,105 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-09-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,179 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of ILUMYA to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Complet | 2021 |
| 2021-09-08 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | 2021 |
| 2021-09-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2021 | |
| 2021-09-07 | Boston Scientific Corporation | $253 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASSESSMENT OF THE WATCHMAN FLX DEVICE IN PATIENTS UNSUITABLE | 2021 |
| 2021-09-06 | Genentech, Inc. | $4,000 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-09-03 | W. L. Gore & Associates, Inc. | $2,250 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB BCA Endoprosthesis in the Treatment of Aortic Arch Aneurysms | 2021 |
| 2021-09-03 | W. L. Gore & Associates, Inc. | $1,250 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-09-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-08-31 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-08-30 | Medical Device Business Services, Inc. | $2,882 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2021 |
| 2021-08-30 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-29 | NEUROPACE, INC. | $95 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2021 |
| 2021-08-27 | Genentech, Inc. | $2,878 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | W. L. Gore & Associates, Inc. | $65 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2021 |
| 2021-08-24 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-24 | GlaxoSmithKline, LLC. | $300 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2021 | |
| 2021-08-23 | Gilead Sciences, Inc. | $2,200 | Research payment | Cash or cash equivalent | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 | |
| 2021-08-19 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU | 2021 | |
| 2021-08-18 | Masimo Corporation | $73,971 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-13 | Allergan, Inc. | $5,427 | Research payment | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAF | 2021 |
| 2021-08-13 | W. L. Gore & Associates, Inc. | $3,400 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-08-12 | GE HEALTHCARE | $1,918 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-08-12 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU | 2021 | |
| 2021-08-10 | Genentech, Inc. | $930 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2021 |
| 2021-08-05 | Masimo Corporation | $73,971 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-05 | Medical Device Business Services, Inc. | $596 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2021 |
| 2021-08-05 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2021 |
| 2021-08-03 | Boston Scientific Corporation | $253 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASSESSMENT OF THE WATCHMAN FLX DEVICE IN PATIENTS UNSUITABLE | 2021 |
| 2021-08-02 | Edwards Lifesciences Corporation | $23,119 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2021 | |
| 2021-08-01 | Boehringer Ingelheim International GmbH | $37 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2021 |
| 2021-07-30 | W. L. Gore & Associates, Inc. | $3,000 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2021 |
The latest 200 records of 548.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lebanon, NH, county Grafton County, NH, state New Hampshire; placed by its city name.
| Measure | Place (city or town) Lebanon, NH | County Grafton County, NH | State New Hampshire |
|---|---|---|---|
| Population B01003 | 14,999 | 92,120 | 1,394,868 |
| Population, 2020 census P1 | 14,282 | 91,118 | 1,377,529 |
| Median age B01002 | 38.9 | 44.1 | 43.3 |
| Under 18 B01001 | 14.6% | 15.6% | 18.2% |
| 65 and over B01001 | 21.4% | 23.0% | 20.1% |
| Households B11001 | 6,917 | 37,107 | 555,822 |
| Foreign born B05002 | 8.6% | 5.6% | 6.1% |
| Median household income B19013 | $98,147 | $88,261 | $99,031 |
| Median family income B19113 | $120,046 | $109,351 | $122,715 |
| Per capita income B19301 | $56,599 | $52,790 | $52,798 |
| Poverty rate B17001 | 7.0% | 10.4% | 7.2% |
| Unemployment rate B23025 | 0.8% | 3.2% | 3.3% |
| Civilian labor force B23025 | 9,352 | 48,140 | 775,826 |
| Mean commute (minutes) B08013 | 14.0 | 22.2 | 26.7 |
| Bachelor's degree or higher B15003 | 57.5% | 46.7% | 40.6% |
| Housing units B25001 | 7,855 | 51,920 | 648,472 |
| Owner-occupied B25003 | 51.2% | 71.3% | 72.8% |
| Renters B25003 | 48.8% | 28.7% | 27.2% |
| Median home value B25077 | $385,400 | $344,500 | $402,500 |
| Median gross rent B25064 | $1,744 | $1,301 | $1,491 |
| White, not Hispanic B03002 | 84.3% | 87.5% | 86.9% |
| Black B03002 | 0.7% | 1.1% | 1.3% |
| Hispanic or Latino B03002 | 3.1% | 2.9% | 4.7% |
| Asian B03002 | 6.7% | 3.5% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lebanon, NH.
Comments